Silo Pharma partners with Columbia University on ketamine-based Alzheimer's therapeutic

Silo Pharma, Inc.

Sponsored research agreement with Columbia University to develop ketamine treatment for Alzheimer's disease.
Option to license novel inventions from Dr. Christine Ann Denny's lab targeting memory and cognitive aging.
No financial terms or specific milestones disclosed in the agreement.
Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on psychedelics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.